AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

• An overview of the current understanding of bleeding and thrombosis in cirrhosis.• An
evidence-based justification for bleeding risk assessment in patients with cirrhosis before …

Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …

Background and Aims Outcomes with anticoagulation (AC) are understudied in advanced
liver disease. We investigated effects of AC with warfarin and direct oral anticoagulants …

Abstract Background & Aims While direct oral anticoagulants (DOACs) are increasingly used
in patients with liver disease, safety data especially in advanced chronic liver disease …

Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent and relevant
healthcare issues. Direct oral anticoagulants (DOACs) are now the first-choice for …

Background & Aims Studies of the effects of direct oral anticoagulants (DOACs) in patients
with cirrhosis have been limited by their small sample size, inclusion of patients with well …

Major bleeding (especially intracranial hemorrhage) is the most feared adverse event
observed in patients with atrial fibrillation (AF) receiving oral anticoagulation. Clinical risk …

Background and Aims Direct oral anticoagulants (DOACs) may simplify management of
Budd-Chiari syndrome (BCS). Here, we report our experience with off-label use of DOACs …